RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 128 filers reported holding RECURSION PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 1.27 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,104,125 | -6.7% | 144,330 | -8.9% | 0.00% | 0.0% |
| Q2 2023 | $1,183,188 | +79.7% | 158,392 | +60.5% | 0.00% | +100.0% |
| Q1 2023 | $658,289 | -12.5% | 98,694 | +1.1% | 0.00% | 0.0% |
| Q4 2022 | $752,434 | -26.5% | 97,592 | +1.4% | 0.00% | -50.0% |
| Q3 2022 | $1,024,000 | +27.7% | 96,266 | -2.3% | 0.00% | +100.0% |
| Q2 2022 | $802,000 | +32.8% | 98,520 | +16.7% | 0.00% | 0.0% |
| Q1 2022 | $604,000 | -63.4% | 84,397 | -12.4% | 0.00% | -50.0% |
| Q4 2021 | $1,650,000 | +371.4% | 96,335 | +533.7% | 0.00% | – |
| Q3 2021 | $350,000 | -67.1% | 15,203 | -47.9% | 0.00% | -100.0% |
| Q2 2021 | $1,064,000 | – | 29,154 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kinnevik AB (publ) | 10,405,668 | $77,730,340 | 100.00% |
| Data Collective IV GP, LLC | 5,941,120 | $44,380,166 | 32.86% |
| MV Management XI, L.L.C. | 1,971,908 | $14,730,153 | 25.77% |
| MIC Capital Management UK LLP | 8,451,758 | $63,134,635 | 12.84% |
| Yong Rong (HK) Asset Management Ltd | 1,174,200 | $8,772 | 3.85% |
| ArchPoint Investors | 1,114,626 | $8,326,256 | 3.22% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,711,148 | $20,252,276 | 0.70% |
| HARVARD MANAGEMENT CO INC | 882,129 | $6,590 | 0.65% |
| Diametric Capital, LP | 119,906 | $895,698 | 0.40% |
| Lingotto Investment Management LLP | 775,077 | $5,789,825 | 0.37% |